Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. has faced significant financial adjustments due to legal disputes and changes in market conditions, leading to a substantial revision of its expected net profit for 2024 from a profit of 40.53 million yuan to a loss of 42.72 million yuan [1][2][3]. Financial Adjustments - The company initially estimated a net profit of 40.53 million yuan, which was later revised to 11.64 million yuan due to a legal ruling requiring compensation of 61.31 million yuan for trademark infringement, significantly higher than the previously expected 30 million yuan [1][2]. - The final adjustment resulted in a net loss of 42.72 million yuan, primarily due to the inability to recognize deferred tax assets from the transfer of three R&D projects from a wholly-owned subsidiary, which was expected to generate 52.74 million yuan in deferred tax assets [1][3][4]. Legal Disputes - The company has been involved in a series of legal battles regarding trademark rights, particularly with Ganli Pharmaceutical over the "Changshulin" trademark, which has resulted in significant financial implications [2][3]. - The legal proceedings included multiple court rulings, with the final judgment requiring the company to pay over 60 million yuan in damages, impacting its financial statements and leading to the recognition of liabilities [2][3]. Market Conditions - The company has been affected by the national drug procurement policy, which has led to a decrease in sales prices for its insulin products, resulting in a revenue decline of approximately 0.90 billion yuan for 2024 [9][11]. - The sales volume of insulin products dropped significantly, with a 58% decrease in the first half of 2024 compared to the second half of 2023, although there was a recovery in the second half of 2024 [9][11]. Strategic Responses - In response to the challenges posed by the procurement policy, the company has implemented a "volume protection and expansion" strategy, achieving significant breakthroughs in hospital access for its insulin products [12][19]. - The company has also launched new products, including GLP-1 receptor agonists and SGLT-2 inhibitors, to enhance its market presence and competitiveness [12][19]. Internal Controls and Financial Management - The company has maintained that its financial accounting practices are prudent and that its internal control systems are effective, despite the significant adjustments to its financial forecasts [15][21]. - The audit committee has confirmed that the adjustments made to the financial statements were based on the best estimates available at the time and that the internal controls regarding sales expenses and financial reporting are robust [15][21].

关于对通化东宝药业股份有限公司 2024 年年报的信息披露监管问询函的回复 德皓函字[2025]00000105 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 关于对通化东宝药业股份有限公司 2024 年年度报告的信息披露监管问询函的回复 德皓函字[2025] 00000105号 上海证券交易所上市公司管理一部： 由通化东宝药业股份有限公司（以下简称"通化东宝"或"公 司"）转来的《关于通化东宝药业股份有限公司 2024 年年度报告的 信息披露监管问询函》（上证公函【2025】0898 号）（以下简称"《问 询函》"）奉悉，本所作为通化东宝 2024 年度财务报表审计的会计 师事务所，现就《问询函》中需要年审会计师发表意见的有关事项 核查说明如下： 1．关于公司业绩。前期公告显示，公司对于年度业绩预告先后 进行两次更正：公司原预计归母净利润 4,053 万元，2 月 26 日进行 第一次更正，将预计 ...

通化东宝药业股份有限公司董事会审计委员会 关于上海证券交易所对公司 2024 年年度报告的信息 披露监管问询函中相关问题的回复意见 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）于近期收 到上海证券交易所《关于通化东宝药业股份有限公司 2024 年年度报告的信息披 露监管问询函》（上证公函【2025】0898 号，以下简称"《问询函》"）。现将《问 询函》相关事项回复如下： 1、关于公司业绩。前期公告显示，公司对于年度业绩预告先后进行两次更 正：公司原预计归母净利润 4,053 万元，2 月 26 日进行第一次更正，将预计归 母净利润调整为 1,164 万元，主要系侵害商标权诉讼终审判决公司赔付 6,131 万，较此前预计的 3,000 万元差异较大；4 月 28 日进行第二次更正，将预计归 母净利润调整为-4,272 万元，主要系 2024 年年底全资子公司将三个研发项目转 让给公司事项，原预计短期内能完成而确认递延所得税资产，但相关手续仍未 完成，导致利润减少约 5,274 万元。此外，报告期公司由盈转亏，业绩大幅下 滑，原因还包括集采续标前对库存进行控制与调整，对流通环节库存产品原供 货价与 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-047 通化东宝药业股份有限公司 关于上海证券交易所对公司 2024 年年度报告 的信息披露监管问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"或"我司"）于 近期收到上海证券交易所《关于通化东宝药业股份有限公司 2024 年年度报告的信息 披露监管问询函》（上证公函【2025】0898 号，以下简称"《问询函》"）。公司 对《问询函》高度重视，积极组织各相关方对《问询函》中涉及的事项进行逐项落实， 具体回复如下： 1．关于公司业绩。前期公告显示，公司对于年度业绩预告先后进行两次更正： 公司原预计归母净利润 4,053 万元，2 月 26 日进行第一次更正，将预计归母净利润 调整为 1,164 万元，主要系侵害商标权诉讼终审判决公司赔付 6,131 万，较此前预计 的 3,000 万元差异较大；4 月 28 日进行第二次更正，将预计归母净利润调整为-4,272 万元，主要系 2024 年年底 ...

通化东宝药业股份有限公司 关于董事会秘书离任的公告 证券代码：600867 证券简称：通化东宝 公告编号：2025-046 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《公司法》、《公司章程》以及法律法规的相关规定，苏璠女士的辞职报 告自送达董事会之日起生效。 根据《上海证券交易所股票上市规则》等有关规定，在聘任新的董事会秘书 之前，由公司董事长李佳鸿先生代行董事会秘书职责。公司董事会将按照相关规 定尽快聘任新的董事会秘书。苏璠女士所负责的工作已经妥善交接，其职务变动 不会对公司正常经营活动产生不利影响。 公司董事会对苏璠女士在担任公司董事会秘书期间为公司发展所做出的贡 献表示衷心的感谢！ 特此公告。 通化东宝药业股份有限公司董事会 2025 年 7 月 5 日 通化东宝药业股份有限公司（以下简称"公司"）董事会近日收到董事会秘 书苏璠女士递交的书面辞职报告，苏璠女士因个人原因，申请辞去公司董事会秘 书的职务。辞职后，苏璠女士将不再担任公司任何职务。 一、提前离任的基本情况 | 姓名 | 离任职务 | ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-045 通化东宝药业股份有限公司关于 协议转让特宝生物部分股份完成过户登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、股份协议转让基本情况 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）于 2025 年 5 月 22 日与西藏信托有限公司（代表"西藏信托-金桐 35 号集合资金信托计 划"）（以下简称"西藏信托"）签署了《股份转让协议》，以协议转让方式转 让厦门特宝生物工程股份有限公司（证券代码：688278，以下简称"特宝生物"） 无限售条件流通股股份 23,187,600 股，占特宝生物当前总股本的 5.70%，转让 价格 56.12 元/股,转让价款总额为人民币 1,301,288,112 元。该事项分别已经公 司 2025 年 5 月 22 日、2025 年 6 月 9 日召开的第十一届董事会第十五次会议、 2025 年第一次临时股东会审议通过。 具体内容详见公司分别于 2025 年 5 月 23 日、2025 年 6 月 10 ...

Core Insights - Tonghua Dongbao and Dongfulong have signed a strategic cooperation agreement to collaborate on product development, equipment innovation, process optimization, and commercial cooperation in the diabetes treatment sector [1][2][3] Company Overview - Tonghua Dongbao specializes in diabetes treatment and has a comprehensive product pipeline, including human insulin, glargine insulin, aspart insulin, liraglutide injection, and related medical devices [1] - The company is advancing innovative drugs in other endocrine areas such as weight loss and gout/hyperuricemia, with ongoing research on ultra-rapid insulin, semaglutide, GLP-1/GIP dual receptor agonists, small molecule GLP-1 receptor agonists, URAT1 inhibitors, and XO/URAT1 dual-target inhibitors [1] Strategic Development - The company emphasizes a dual strategy of "independent research and development + external cooperation" to enhance research efficiency and expand its business scope [2] - Tonghua Dongbao's chairman highlighted the commitment to innovation and patient needs, with increased investment in R&D for insulin analogs and GLP-1 receptor agonists [2] Industry Collaboration - Dongfulong provides comprehensive solutions for pharmaceutical companies, with four core divisions and multiple subsidiaries, focusing on drug manufacturing science and equipment [2] - The collaboration between Tonghua Dongbao and Dongfulong aims to integrate resources to advance technology and industry development in diabetes treatment, enhancing the competitiveness of China's pharmaceutical industry [3]

Group 1 - Dongfulong (300171) and Tonghua Dongbao (600867) have officially signed a strategic cooperation agreement [1] - The collaboration will focus on product research and development, equipment innovation, process optimization, and commercial cooperation [1] - The partnership aims to promote technological advancement and industrial development in the diabetes treatment field [1]

Group 1 - The company has completed the sale of all shares held under the 2020 employee stock ownership plan [1][7] - The employee stock ownership plan was approved by the company's board and shareholders in late 2020 [1][2] - The management committee for the employee stock ownership plan was established to oversee daily management and represent shareholders [2] Group 2 - The first unlocking period of the employee stock ownership plan allowed for the release of 364.40 million shares, representing 40% of the total shares held [4] - The second unlocking period allowed for the release of 273.30 million shares, representing 30% of the total shares held [4] - The plan was terminated early in January 2024, with 273.30 million shares remaining unallocated [5][6] Group 3 - The shares were sold through a centralized bidding process in the secondary market, adhering to trading regulations [7] - The management committee will complete asset liquidation and distribution following the sale of the shares [7]

一、2020 年员工持股计划的基本情况 （一）公司于 2020 年 9 月 29 日召开的第十届董事会第六次会议、第十届监事会第 六次会议及 2020 年 10 月 30 日召开的 2020 年第二次临时股东大会审议通过了《关于 〈通化东宝 2020 年员工持股计划（草案）〉及其摘要的议案》等相关议案。具体内容 详见公司于 2020 年 9 月 30 日、2020 年 10 月 31 日在上海证券报和上海证券交易所网 站 （www.sse.com.cn）披露的相关公告。 （二）2021 年 1 月 21 日，公司召开 2020 年员工持股计划第一次持有人会议，审议 通过了《关于设立 2020 年员工持股计划管理委员会的议案》及相关议案，设立 2020 年员工持股计划管理委员会（以下简称"管理委员会"），负责员工持股计划的日常 管理，代表持有人行使股东权利。管理委员会存续期与 2020 年员工持股计划存续期一 致。具体内容详见公司于 2021 年 1 月 22 日在上海证券报和上海证券交易所网站 证券代码：600867 证券简称：通化东宝 公告编号：2025-044 通化东宝药业股份有限公司 关于 2020 年 ...